Nervous Disorder TRIZ Cases

Classifying multiple sclerosis via RNA polymerase I gene expression enables tailored treatment regimens and avoids unnecessary drug side effects.

Fluoroalkoxy pyridinyl indolsulfonamides overcome low affinity and poor brain penetration of existing modulators by optimizing plasma protein binding.

Segmented antibody design targets K11-linked polyubiquitin chains to resolve detection specificity gaps in cell cycle research.

Combines pemirolast with losartan to inhibit angiotensin II formation and reduce inflammatory responses in cardiovascular disorders.

A recombinant NP protein maintains acetylcholinesterase activity to treat neurological disorders.

Alkaline phosphatase modulates the PGC/AMPK/Sirt pathway to reduce neuroinflammation and extend lifespan in neurodegenerative disorders.

Purified neural precursor cells integrate into damaged nervous tissue to repair root causes of disorders like epilepsy, bypassing simple symptom management.

Administering an EHMT2/G9A inhibitor reduces stress-induced alcohol drinking by targeting nucleus accumbens epigenetic mechanisms.

Combining an SV2A inhibitor with an antipsychotic treats schizophrenia symptoms.

Biocompatible non-aqueous solvents solubilize small molecule drugs, eliminating reconstitution needs and enabling smaller dosage volumes.

Biphenyl compounds target pulmonary muscarinic receptors to deliver bronchodilation while minimizing systemic absorption and side effects.

Formula I compounds stabilize mutant phenylalanine hydroxylase proteins, reducing blood phenylalanine levels without strict dietary restrictions.

Combining nalmefene with vortioxetine targets kappa-opioid receptors to address depressive disorders.

Modifying antibody constant regions reduces immunogenicity and cytokine release while sustaining duration of action.

A stable liquid composition containing levodopa and carbidopa enables continuous subcutaneous administration.

Laminin-modified PLGA microspheres bound to silk fibroin fibers promote axon growth while sustaining active substance release.

Triple-substitution QPO mimics carbamoylated EPO neuroactivity while eliminating hematopoietic risks and batch variability.

Alpha-methyl-DL-tyrosine reduces catecholamine synthesis to address core autism symptoms and lower mortality risks from comorbidities.

A propolis and ginkgo leaf extract composition acts as an antioxidant agent to promote neurite outgrowth.

Antigenic peptide fragments target amyloid-beta to prevent plaque formation in young Down syndrome patients.

Periodic PD-1 agonist administration suppresses autoimmune progression while preserving anti-pathogen immunity and reducing infection risk.

Blocking barbiturate-induced hepatic metabolism of cannabidiol preserves bioavailable drug levels for effective seizure control.

Replacing SMAD inhibitors with ALK blockers resolves the reliability and productivity trade-off in neural cell generation.

Magnesium N-acetyl-taurinate dihydrate enhances bioavailability and cellular penetration to stimulate neuronal plasticity.

Humanized anti-CD52 antibodies exclude CD4+ T cell epitopes to reduce immunogenicity below 4% while maintaining therapeutic efficacy.

Specific milk-derived peptides enhance memory and learning functions through targeted biological activity.

PW164 inhibits FGF13-1b to suppress pain without opioid abuse risks.

Combining HAT activators and HDAC inhibitors overcomes poor solubility of existing agents while increasing histone acetylation levels.

Inhibiting AAK1 kinase activity reduces neuropathic pain while avoiding side effects from conventional opioids.

Humanized antibodies target pathological beta-amyloid neoepitopes to reduce plaque load without inducing autoimmune responses.

Segmenting culture stages with cerebrospinal fluid resolves the efficiency versus specificity contradiction in generating pure neuronal lineages.

Heteroaryl pyrrolidine and piperidine compounds target orexin receptors to treat neurological disorders lacking specific agonists.

Combining EPA with multiple agents treats mixed dyslipidemia while managing hypertension and coronary heart disease.

A calpain inhibitor compound restores neuronal migration by increasing LIS1 protein expression in lissencephaly treatment.

Removing glucose and saline from parenteral cannabinoid formulations prevents hyperglycemia while maintaining stability via chelating agents.

Genotyping SLCO1B1 variants prevents statin-induced myopathy by enabling precise dosage adjustments based on individual metabolic susceptibility.

Nucleoside reverse transcriptase inhibitors block Alu RNA-induced inflammasome activation, addressing geographic atrophy treatment gaps.

Detecting differential gene expression in T cell subsets identifies specific molecular markers for neurodegenerative disease assessment.

Fumaric acid in polar solvent isomerizes eplivanserin base to the Z isomer, avoiding E isomer nucleation.

HSV-NT3 vectors target dorsal root ganglia to express neurotrophin 3, preventing chemotherapy-induced peripheral neuropathy and preserving sensory function.

Sesame oil glycerol esters solubilize water-insoluble antipsychotics into flocculated suspensions, reducing injection site irritation.

Merging the firing pin holder with the biasing member eliminates separate positioning pins, reducing manufacturing complexity.

Meclizine inhibits PCYT2 activity to redirect metabolism, avoiding acute toxicity from classic OXPHOS inhibitors.

Intrathecal autologous mesenchymal stem cells bypass blood-brain barriers to slow disease progression in multiple system atrophy.

Multicyclic amino acid derivatives selectively inhibit peripheral tryptophan hydroxylase 1, reducing adverse central nervous system effects.

Alkanoyl L-carnitine compounds drive neural progenitor differentiation into neurons, addressing limited regeneration rates in adult tissue.